This company listing is no longer active
NVN Liquidation (0A4P) Stock Overview
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
0A4P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
NVN Liquidation, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0008 |
| 52 Week High | €1.28 |
| 52 Week Low | €0.0001 |
| Beta | 1.65 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.93% |
| 3 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4P | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | 0.2% |
| 1Y | -99.9% | 2.8% | 17.3% |
Return vs Industry: 0A4P underperformed the UK Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: 0A4P underperformed the UK Market which returned 1.9% over the past year.
Price Volatility
| 0A4P volatility | |
|---|---|
| 0A4P Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4P's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A4P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 90 | Scott Plesha | www.novan.com |
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.
NVN Liquidation, Inc. Fundamentals Summary
| 0A4P fundamental statistics | |
|---|---|
| Market cap | US$29.97 |
| Earnings (TTM) | -US$32.05m |
| Revenue (TTM) | US$24.92m |
Is 0A4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4P income statement (TTM) | |
|---|---|
| Revenue | US$24.92m |
| Cost of Revenue | US$24.45m |
| Gross Profit | US$473.00k |
| Other Expenses | US$32.52m |
| Earnings | -US$32.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 1.90% |
| Net Profit Margin | -128.61% |
| Debt/Equity Ratio | -1,164.1% |
How did 0A4P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/02 08:34 |
| End of Day Share Price | 2024/04/08 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NVN Liquidation, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Donald Ellis | Citizens JMP Securities, LLC |